Second-lineZofran
Ondansetron
5-HT3 receptor antagonist
Second-line antiemetic for hyperemesis gravidarum.
OralIVODT (wafer)
First-line for
- Hyperemesis gravidarum unresponsive to 1st-line antiemetics
Mechanism
Blocks central & peripheral 5-HT3 receptors in CTZ and gut → ↓ vomiting reflex.
“After 10 wks”
- Avoid before 10 weeks if possible (cleft palate signal, NNH ~1/1000)
- OK after 10 weeks
- Watch QT — avoid with other QT-prolonging drugs
Dosing
- Oral / IV
- 4–8 mg q8h
- Max
- 16 mg/day (QT risk above)
Contraindications
- AbsoluteCongenital long QT
- CautionCombine with apomorphine — hypotension
Side effects
- Constipation, headache
- QT prolongation
- Rare: serotonin syndrome with SSRIs
Fetal & maternal notes
- • Small absolute ↑ risk of cleft palate (use after 10 wks ideally).
- • No ↑ in overall malformation rate.
- • Safe in breastfeeding.
Key interactions
QT-prolonging drugs
AvoidAdditive QT — avoid
SSRIs / SNRIs
CautionSerotonin syndrome (rare)
Clinical pearls
- 💡 1st-line: cyclizine, promethazine, prochlorperazine.
- 💡 Always assess hydration, ketosis, weight loss in HG.
Content last reviewed: REPLACE_ME (e.g. 2026-07)
Spotted something out of date? See our disclaimer or use Report an Error above.